KALRN mutations promote antitumor immunity and immunotherapy response in cancer

BACKGROUND: kalirin RhoGEF kinase (KALRN) is mutated in a wide range of cancers. Nevertheless, the association between KALRN mutations and the pathogenesis of cancer remains unexplored. Identification of biomarkers for cancer immunotherapy response is crucial because immunotherapies only show benefi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengyuan, Ma, Yuxiang, Zhong, You, Liu, Qian, Chen, Canping, Qiang, Lei, Wang, Xiaosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549479/
https://www.ncbi.nlm.nih.gov/pubmed/33037113
http://dx.doi.org/10.1136/jitc-2019-000293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549479/
https://www.ncbi.nlm.nih.gov/pubmed/33037113
http://dx.doi.org/10.1136/jitc-2019-000293

Ejemplares similares